EV/EBITDA Multiple: Organovo Holdings Inc (ONVO)

Corporate company logo of organovo.com (ONVO)

Organovo Holdings, Inc. (ONVO) leads the creation of living tissues via 3D printing, utilizing the NovoGen system to optimize pharmaceutical research. This price chart on GURU.Markets confirms an EV/EBITDA valuation of . Strict patent restrictions and certification complexities ensure a high barrier to entry. The business is currently in an active development phase, consuming existing capital reserves without a stable operational cash flow.

ONVO (Organovo Holdings) Enterprise Value to Operating Income Before Depreciation Ratio history from 07/04/2022 to 11/18/2026

Organovo Holdings (ONVO) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:ONVO (Organovo Holdings, Inc.)
Product sample of Organovo

To identify the sector's fundamental leaders, the analyst compares the enterprise value (EV) of the business with its earnings before interest, taxes, depreciation, and amortization. This ratio assesses the real value of assets relative to the ability to generate cash flow, which is critical for Organovo Holdings, Inc. (ONVO) during its bioprinted tissue development phase. The current value of on the EV/EBITDA chart alongside historical data allows for an assessment of how future licensing deals will impact capitalization.

Who Organovo Holdings, Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences, Inc. SGMT|BioAge - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion Corp - EV/EBITDA Multiple|QNCX - EV/EBITDA Multiple|GUTS: EV/EBITDA Multiple|VTVT (vTv Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp.|PLUR: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Synlogic, Inc. (SYBX)|Enterprise Value to EBITDA Ratio Lipocine Corp LPCN|EV/EBITDA Multiple MTNB (Matinas BioPharma Holdings, Inc.)|Spruce Biosciences (SPRB) - Company Value to EBITDA|GLTO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTCX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LUMO: EV/EBITDA Multiple|Radius Health - Business Value to Operating Income Before Depreciation